Skip to main content

Table 5 Odds ratios for having the metabolic syndrome in patients receiving methotrexate compared with those not on methotrexate

From: Methotrexate therapy associates with reduced prevalence of the metabolic syndrome in rheumatoid arthritis patients over the age of 60- more than just an anti-inflammatory effect? A cross sectional study

 

Odds ratio

95% confidence interval

P value

Crude

0.483

0.32 to 0.73

0.001

Model a

0.505

0.33 to 0.77

0.001

Model b

0.525

0.34 to 0.80

0.003

Model c

0.517

0.33 to 0.80

0.004

  1. Crude = unadjusted model
  2. Model a = adjusted for age and sex
  3. Model b = adjusted for age, sex, disease duration, erythrocyte sedimentation rate and health assessment questionnaire score
  4. Model c = adjusted for age, sex, disease duration, erythrocyte sedimentation rate, health assessment questionnaire score, sulphasalazine, hydroxyxhloroquine, leflunomide, anti-tumour necrosis factor therapy, glucocorticoid use and NSAID use.
Back to article page